Earnings Summary

Arcutis Biotherapeutics Inc’s revenue jumped 356.81% since last year same period to $13.53Mn in the Q4 2023. On a quarterly growth basis, Arcutis Biotherapeutics Inc has generated -64.51% fall in its revenue since last 3-months.

Arcutis Biotherapeutics Inc’s net profit jumped 12.34% since last year same period to $-66.28Mn in the Q4 2023. On a quarterly growth basis, Arcutis Biotherapeutics Inc has generated -48.07% fall in its net profits since last 3-months.

Arcutis Biotherapeutics Inc’s net profit margin jumped 80.81% since last year same period to -490.05% in the Q4 2023. On a quarterly growth basis, Arcutis Biotherapeutics Inc has generated -317.18% fall in its net profit margins since last 3-months.

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.74 - a 3.9% jump from last quarter’s estimates.

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.74.

Arcutis Biotherapeutics Inc’s earning per share (EPS) jumped 38.98% since last year same period to -0.72 in the Q4 2023. This indicates that the Arcutis Biotherapeutics Inc has generated 38.98% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcutis Biotherapeutics Inc’s return on assets (ROA) stands at -0.38.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcutis Biotherapeutics Inc’s return on equity (ROE) stands at -1.76.